BioLineRx Competitors

Flexion Therapeutics (NASDAQ:FLXN) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Flexion Therapeutics and BioLineRx, as reported by MarketBeat.

Flexion Therapeutics currently has a consensus target price of $20.4545, suggesting a potential upside of 117.60%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than Flexion Therapeutics.

Earnings & Valuation

This table compares Flexion Therapeutics and BioLineRx's top-line revenue, earnings per share and valuation.

BioLineRx has lower revenue, but higher earnings than Flexion Therapeutics. Flexion Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Flexion Therapeutics has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Profitability

This table compares Flexion Therapeutics and BioLineRx's net margins, return on equity and return on assets.

Insider and Institutional Ownership

17.5% of BioLineRx shares are held by institutional investors. 17.0% of Flexion Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioLineRx beats Flexion Therapeutics on 7 of the 13 factors compared between the two stocks.

89bio (NASDAQ:ETNB) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for 89bio and BioLineRx, as reported by MarketBeat.

89bio currently has a consensus target price of $62.4286, suggesting a potential upside of 165.54%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than 89bio.

Earnings & Valuation

This table compares 89bio and BioLineRx's top-line revenue, earnings per share and valuation.

BioLineRx is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares 89bio and BioLineRx's net margins, return on equity and return on assets.

Insider and Institutional Ownership

80.6% of 89bio shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 18.1% of 89bio shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

89bio beats BioLineRx on 7 of the 11 factors compared between the two stocks.

Forte Biosciences (NASDAQ:FBRX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Forte Biosciences and BioLineRx, as reported by MarketBeat.

Forte Biosciences currently has a consensus target price of $82.00, suggesting a potential upside of 136.65%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than Forte Biosciences.

Earnings & Valuation

This table compares Forte Biosciences and BioLineRx's top-line revenue, earnings per share and valuation.

BioLineRx has lower revenue, but higher earnings than Forte Biosciences. BioLineRx is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Forte Biosciences has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Profitability

This table compares Forte Biosciences and BioLineRx's net margins, return on equity and return on assets.

Insider and Institutional Ownership

53.0% of Forte Biosciences shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 10.9% of Forte Biosciences shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioLineRx beats Forte Biosciences on 7 of the 11 factors compared between the two stocks.

Fortress Biotech (NASDAQ:FBIO) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Insider and Institutional Ownership

32.1% of Fortress Biotech shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 29.5% of Fortress Biotech shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Fortress Biotech and BioLineRx's net margins, return on equity and return on assets.

Risk & Volatility

Fortress Biotech has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.

Earnings & Valuation

This table compares Fortress Biotech and BioLineRx's top-line revenue, earnings per share and valuation.

BioLineRx has lower revenue, but higher earnings than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for Fortress Biotech and BioLineRx, as reported by MarketBeat.

Fortress Biotech currently has a consensus target price of $10.75, suggesting a potential upside of 118.05%. BioLineRx has a consensus target price of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than Fortress Biotech.

Summary

Fortress Biotech beats BioLineRx on 8 of the 12 factors compared between the two stocks.

Akebia Therapeutics (NASDAQ:AKBA) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Insider and Institutional Ownership

69.0% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 2.6% of Akebia Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Akebia Therapeutics and BioLineRx's net margins, return on equity and return on assets.

Volatility and Risk

Akebia Therapeutics has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Earnings and Valuation

This table compares Akebia Therapeutics and BioLineRx's gross revenue, earnings per share (EPS) and valuation.

BioLineRx has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Akebia Therapeutics and BioLineRx, as reported by MarketBeat.com.

Akebia Therapeutics currently has a consensus price target of $9.6250, suggesting a potential upside of 217.66%. BioLineRx has a consensus price target of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's stronger consensus rating and higher probable upside, analysts clearly believe BioLineRx is more favorable than Akebia Therapeutics.

Summary

Akebia Therapeutics beats BioLineRx on 9 of the 13 factors compared between the two stocks.

Verastem (NASDAQ:VSTM) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, dividends, analyst recommendations, institutional ownership and profitability.

Insider and Institutional Ownership

42.2% of Verastem shares are held by institutional investors. Comparatively, 17.5% of BioLineRx shares are held by institutional investors. 2.9% of Verastem shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Verastem and BioLineRx's net margins, return on equity and return on assets.

Volatility and Risk

Verastem has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 2.08, indicating that its share price is 108% more volatile than the S&P 500.

Earnings and Valuation

This table compares Verastem and BioLineRx's gross revenue, earnings per share (EPS) and valuation.

BioLineRx has lower revenue, but higher earnings than Verastem. Verastem is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Verastem and BioLineRx, as reported by MarketBeat.com.

Verastem currently has a consensus price target of $3.00, suggesting a potential upside of 11.11%. BioLineRx has a consensus price target of $19.00, suggesting a potential upside of 588.41%. Given BioLineRx's higher probable upside, analysts clearly believe BioLineRx is more favorable than Verastem.

Summary

BioLineRx beats Verastem on 7 of the 11 factors compared between the two stocks.